Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Frequently asked questions
What sector does Emmaus Life Sciences Inc (EMMA) operate in?
Emmaus Life Sciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Emmaus Life Sciences Inc (EMMA) current stock price?
As of the latest data, Emmaus Life Sciences Inc stock price is $0.01, with a previous close of $0.01.
What is Emmaus Life Sciences Inc (EMMA) current market capitalization?
Emmaus Life Sciences Inc market cap is approximately 807.17 thousand.
What is Emmaus Life Sciences Inc (EMMA) Earnings Per Share (EPS)?
The trailing EPS is -$0.13.
Does Emmaus Life Sciences Inc (EMMA) pay dividends?
No. Emmaus Life Sciences Inc does not pay a dividend.
What is Emmaus Life Sciences Inc (EMMA) beta (volatility) score?
Emmaus Life Sciences Inc has a beta of 9.678, indicating very high volatility compared to the market.
